[go: up one dir, main page]

WO2004080382A3 - Novel compositions containing fentanyl - Google Patents

Novel compositions containing fentanyl Download PDF

Info

Publication number
WO2004080382A3
WO2004080382A3 PCT/GB2004/001037 GB2004001037W WO2004080382A3 WO 2004080382 A3 WO2004080382 A3 WO 2004080382A3 GB 2004001037 W GB2004001037 W GB 2004001037W WO 2004080382 A3 WO2004080382 A3 WO 2004080382A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions containing
novel compositions
containing fentanyl
fentanyl
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2004/001037
Other languages
French (fr)
Other versions
WO2004080382A2 (en
Inventor
Calvin Ross
Clive Booles
Alistair Campbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SIRUS PHARMACEUTICALS Ltd
Original Assignee
SIRUS PHARMACEUTICALS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0305579.5A external-priority patent/GB0305579D0/en
Priority to JP2006500257A priority Critical patent/JP2006519770A/en
Priority to HK05112165.9A priority patent/HK1084012A1/en
Priority to EP04719527A priority patent/EP1608372A2/en
Priority to NZ541781A priority patent/NZ541781A/en
Priority to CA002516338A priority patent/CA2516338A1/en
Priority to BRPI0408209-5A priority patent/BRPI0408209A/en
Priority to CN2004800051154A priority patent/CN1784228B/en
Priority to AU2004218876A priority patent/AU2004218876B2/en
Application filed by SIRUS PHARMACEUTICALS Ltd filed Critical SIRUS PHARMACEUTICALS Ltd
Priority to MXPA05009602A priority patent/MXPA05009602A/en
Publication of WO2004080382A2 publication Critical patent/WO2004080382A2/en
Publication of WO2004080382A3 publication Critical patent/WO2004080382A3/en
Priority to NO20054172A priority patent/NO20054172L/en
Anticipated expiration legal-status Critical
Priority to US11/224,383 priority patent/US20060062812A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to formulations of fentanyl, especially pump spray formulations suitable for sublingual delivery.
PCT/GB2004/001037 2003-03-11 2004-03-11 Novel compositions containing fentanyl Ceased WO2004080382A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MXPA05009602A MXPA05009602A (en) 2003-03-11 2004-03-11 Novel compositions containing fentanyl.
BRPI0408209-5A BRPI0408209A (en) 2003-03-11 2004-03-11 new compositions
HK05112165.9A HK1084012A1 (en) 2003-03-11 2004-03-11 Compositions containing fentanyl
EP04719527A EP1608372A2 (en) 2003-03-11 2004-03-11 Compositions containing fentanyl
NZ541781A NZ541781A (en) 2003-03-11 2004-03-11 Novel compositions containing fentanyl
CA002516338A CA2516338A1 (en) 2003-03-11 2004-03-11 Novel compositions containing fentanyl
CN2004800051154A CN1784228B (en) 2003-03-11 2004-03-11 Novel compositions
JP2006500257A JP2006519770A (en) 2003-03-11 2004-03-11 New composition
AU2004218876A AU2004218876B2 (en) 2003-03-11 2004-03-11 Novel compositions containing fentanyl
NO20054172A NO20054172L (en) 2003-03-11 2005-09-07 New mixtures
US11/224,383 US20060062812A1 (en) 2003-03-11 2005-09-12 Novel compositions

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0305579.5 2003-03-11
GBGB0305579.5A GB0305579D0 (en) 2003-03-11 2003-03-11 Pharmaceutical compositions
GB0328023A GB2399286A (en) 2003-03-11 2003-12-03 Sub-lingual fentanyl formulation
GB0328023.7 2003-12-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/224,383 Continuation-In-Part US20060062812A1 (en) 2003-03-11 2005-09-12 Novel compositions

Publications (2)

Publication Number Publication Date
WO2004080382A2 WO2004080382A2 (en) 2004-09-23
WO2004080382A3 true WO2004080382A3 (en) 2005-03-24

Family

ID=32992592

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/001037 Ceased WO2004080382A2 (en) 2003-03-11 2004-03-11 Novel compositions containing fentanyl

Country Status (10)

Country Link
EP (1) EP1608372A2 (en)
JP (1) JP2006519770A (en)
KR (1) KR20050115276A (en)
AU (1) AU2004218876B2 (en)
BR (1) BRPI0408209A (en)
CA (1) CA2516338A1 (en)
MX (1) MXPA05009602A (en)
NO (1) NO20054172L (en)
NZ (1) NZ541781A (en)
WO (1) WO2004080382A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5577021B2 (en) * 2005-02-17 2014-08-20 アボット・ラボラトリーズ Transmucosal administration of pharmaceutical compositions for treating and preventing disorders in animals
GB0514043D0 (en) * 2005-07-08 2005-08-17 Arakis Ltd Fentanyl formulation
NZ569949A (en) * 2006-01-25 2011-10-28 Insys Therapeutics Inc Sublingual fentanyl spray
CA2698749C (en) 2007-08-02 2017-05-23 Insys Therapeutics Inc. Sublingual fentanyl spray
GB2476494A (en) * 2009-12-24 2011-06-29 Norwich Pharma Technologies Ltd Formulation for the sublingual delivery of sufentanil

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999016417A1 (en) * 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US5958379A (en) * 1994-09-30 1999-09-28 Mika Pharma Gesellschaft Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Producte Mbh Pharmaceutical composition
WO2000016751A1 (en) * 1998-09-24 2000-03-30 Diabact Ab Fentanyl composition for the treatment of acute pain
WO2000047203A1 (en) * 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
WO2002011778A1 (en) * 2000-05-10 2002-02-14 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
WO2002051380A1 (en) * 2000-12-22 2002-07-04 Audit Institute For Medical Services And Quality Assurance Gmbh Novel pharmaceutical composition consisting of water-soluble or poorly water-soluble active substances
US20030035831A1 (en) * 1998-12-21 2003-02-20 Pankaj Modi Pharmaceutical compositions for buccal delivery of pain relief medications
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958379A (en) * 1994-09-30 1999-09-28 Mika Pharma Gesellschaft Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Producte Mbh Pharmaceutical composition
WO1999016417A1 (en) * 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US20030185761A1 (en) * 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
WO2000016751A1 (en) * 1998-09-24 2000-03-30 Diabact Ab Fentanyl composition for the treatment of acute pain
US20030035831A1 (en) * 1998-12-21 2003-02-20 Pankaj Modi Pharmaceutical compositions for buccal delivery of pain relief medications
WO2000047203A1 (en) * 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
WO2002011778A1 (en) * 2000-05-10 2002-02-14 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
WO2002051380A1 (en) * 2000-12-22 2002-07-04 Audit Institute For Medical Services And Quality Assurance Gmbh Novel pharmaceutical composition consisting of water-soluble or poorly water-soluble active substances

Also Published As

Publication number Publication date
NZ541781A (en) 2008-04-30
MXPA05009602A (en) 2005-11-08
CA2516338A1 (en) 2004-09-23
WO2004080382A2 (en) 2004-09-23
NO20054172D0 (en) 2005-09-07
JP2006519770A (en) 2006-08-31
NO20054172L (en) 2005-10-06
BRPI0408209A (en) 2006-02-14
KR20050115276A (en) 2005-12-07
AU2004218876B2 (en) 2007-08-02
AU2004218876A1 (en) 2004-09-23
EP1608372A2 (en) 2005-12-28

Similar Documents

Publication Publication Date Title
MXPA05012025A (en) Imidazo and thiazolopyridines as jak3 kinase inhibitors.
UA86591C2 (en) Pyrrolodihydroisoquinolines as pde10 inhibitors, pharmaceutical composition based thereon
MXPA05012026A (en) Azaindole compounds as kinase inhibitors.
WO2004074244A3 (en) Pyrimidine compounds
WO2004082822A3 (en) Methods for isolating crystalline form i of 5-azacytidine
WO2008064353A3 (en) 7,8-saturated-4,5-epoxy-morphinanium analogs
EP1615621A4 (en) Compositions for delivery of drug combinations
SE0101675D0 (en) Novel composition
WO2006050161A3 (en) Therapeutic furopyrimidines and thienopyrimidines
WO2008070462A3 (en) N-oxides of 4,5-epoxy-morphinanium analogs
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2006021213A3 (en) Vasopressin v1a antagonists
PH12013501567A1 (en) Anti-malarial pharmaceutical composition
WO2005030188A3 (en) Phenyl-piperazine derivatives as modulators of muscarinic receptors
WO2003017924A3 (en) Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
WO2004080382A3 (en) Novel compositions containing fentanyl
WO2004087652A3 (en) Imidazotriazine compounds
GB0514043D0 (en) Fentanyl formulation
MY142076A (en) Emulsifying systems containing azetidine derivatives
WO2005060981A3 (en) Pharmaceutical compositions
WO2007087026A3 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
WO2004089281A3 (en) Novel polymorphs of tolterodine tartrate
WO2003097593A3 (en) Protease inhibitors
WO2006059304A3 (en) Novel lactame derivatives as renin inhibitors
WO2006005017A3 (en) Oral composition comprising carbamylating agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 3409/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 170058

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005/06248

Country of ref document: ZA

Ref document number: 200506248

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 541781

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2516338

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004218876

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20048051154

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/009602

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020057016853

Country of ref document: KR

Ref document number: 2006500257

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11224383

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2004218876

Country of ref document: AU

Date of ref document: 20040311

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004218876

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004719527

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057016853

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004719527

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0408209

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 11224383

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2004218876

Country of ref document: AU